Targeted Nanoparticles Reprogram Immune Cells to Reverse Atherosclerosis
Novel liposome therapy delivers miR-10a to atherosclerotic plaques, reprogramming inflammatory macrophages and reducing disease progression in mice.
Summary
Researchers developed targeted nanoparticles that deliver miR-10a directly to atherosclerotic plaques, successfully reprogramming inflammatory macrophages into anti-inflammatory ones. The therapy works by restoring mitochondrial function and reopening chromatin in immune cells that had become locked in a pro-inflammatory state. In mouse studies, intravenous treatment significantly reduced atherosclerosis progression by switching macrophage phenotypes from harmful M1 to beneficial M2 types.
Detailed Summary
Atherosclerosis progression is driven by macrophages trapped in a pro-inflammatory M1 state within arterial plaques. These immune cells become epigenetically locked due to chronic inflammatory training, making traditional therapies ineffective at reprogramming them to beneficial M2 phenotypes.
Researchers at Sichuan University engineered red blood cell membrane-coated liposomes loaded with miR-10a (miR-10a@H-MNP) to overcome this challenge. The nanoparticles include hyaluronic acid targeting to specifically bind inflammatory macrophages and evade immune clearance through biomimetic coating.
Using human atherosclerotic plaque samples and single-cell RNA sequencing, the team confirmed that M1 macrophages show elevated histone deacetylases (HDAC1-3) and reduced mitochondrial function genes compared to M2 cells. The miR-10a treatment restored mitochondrial respiration, increased histone acetylation, and reopened chromatin accessibility in inflammatory macrophages.
In vitro studies demonstrated that miR-10a significantly enhanced mitochondrial oxygen consumption, ATP production, and respiratory capacity in M1 macrophages. Flow cytometry confirmed successful phenotype switching from CD86+ (M1) to CD206+ (M2) markers. Crucially, blocking fatty acid oxidation with etomoxir prevented the therapeutic effects, confirming the mitochondrial mechanism.
Intravenous administration of miR-10a@H-MNP in atherosclerotic mice led to substantial plaque reduction and macrophage reprogramming. This represents a breakthrough in atherosclerosis therapy by targeting the root epigenetic dysfunction rather than just inflammatory symptoms.
Key Findings
- miR-10a restored mitochondrial respiration and ATP production in inflammatory macrophages
- Targeted liposomes successfully reprogrammed M1 to M2 macrophages in atherosclerotic plaques
- Treatment significantly reduced atherosclerosis progression in mouse models
- Therapy works by reopening chromatin through restored mitochondrial acetyl-CoA production
- Red blood cell membrane coating enabled immune evasion and plaque targeting
Methodology
Study used human atherosclerotic samples, single-cell RNA sequencing, engineered red blood cell membrane-coated liposomes with hyaluronic acid targeting, and atherosclerotic mouse models with intravenous treatment delivery.
Study Limitations
Study conducted only in male mice, long-term safety and efficacy in humans unknown, and the complex nanoparticle manufacturing may present scalability challenges for clinical translation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.